Gastrointestinal mucosal proteins and bacterial enzymes

Gastrointestinal mucosal proteins and bacterial enzymes represent a collective pharmacological target category primarily associated with the mechanism of action of bismuth-containing compounds and certain cytoprotective agents (DrugBank Online, DB01294). This target encompasses a variety of endogenous proteins within the gastric and intestinal mucosa, as well as exogenous enzymes produced by enteric bacteria, most notably the urease enzyme of Helicobacter pylori (StatPearls, NBK537180). When drugs like bismuth subsalicylate are ingested, they react with gastric acid to form bismuth salts that bind to these mucosal proteins, creating a physical barrier that protects ulcerated tissue from further degradation by acid and pepsin (PubChem, CID 16685300). Furthermore, the interaction with bacterial enzymes leads to the inhibition of microbial metabolic pathways, which is instrumental in treating infections and diarrhea (Mayo Clinic). Because this designation refers to a heterogeneous group of molecules rather than a single defined receptor or enzyme, it is generally considered a non-specific target in molecular pharmacology.

Other names

Gastrointestinal mucosal proteinsBacterial enzymes of the gutGI mucosal proteins and bacterial enzymes

Bismuth compounds and sucralfate bind to proteins within the gastrointestinal mucosa, particularly at the site of ulcerations, to form a protective chelate layer that shields the tissue from gastric acid and pepsin. They also inhibit various bacterial enzymes, such as urease produced by H. pylori, thereby exerting antimicrobial effects and disrupting the pathogen's ability to survive in the acidic environment of the stomach.